Diuretic

Metolazone for Chronic Kidney Disease

Phase 2
Recruiting
Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Upchange from baseline quality of life score at 1 week for each study arm
Awards & highlights
Approved for 5 Other Conditions
All Individual Drugs Already Approved

Study Summary

This trial will study how well diuretics work in patients with chronic kidney disease.

Eligible Conditions
  • Chronic Kidney Disease
  • Kidney Failure

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline urine output at 1 week for each study arm
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline urine output at 1 week for each study arm for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in urine output
Secondary outcome measures
Change in kidney clearance of uremic solutes
Change in quality of life questionnaire score

Awards & Highlights

Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Metolazone then placeboActive Control1 Intervention
Metolazone will be taken orally during the first week, followed by washout of 1-2 weeks, then placebo will be taken the following week.
Group II: Placebo then MetolazonePlacebo Group1 Intervention
Placebo will be taken orally during the first week, followed by washout of 1-2 weeks, then metolazone will be taken the following week.

Find a site

Who is running the clinical trial?

Stanford UniversityLead Sponsor
2,294 Previous Clinical Trials
17,286,228 Total Patients Enrolled

Media Library

Metolazone (Diuretic) Clinical Trial Eligibility Overview. Trial Name: NCT04542304 — Phase 2
Chronic Kidney Disease Research Study Groups: Placebo then Metolazone, Metolazone then placebo
Chronic Kidney Disease Clinical Trial 2023: Metolazone Highlights & Side Effects. Trial Name: NCT04542304 — Phase 2
Metolazone (Diuretic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04542304 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What types of ailments is this therapy generally employed to address?

"This medical intervention is useful for those with kidney diseases, hypertension and fluid retention."

Answered by AI

What is the enrollment capacity for this clinical research?

"Affirmative. According to the information hosted on clinicaltrials.gov, recruitment for this medical trial is underway; it was initially posted in March 2021 and last revised September 2022. Fifty participants are sought from two different healthcare facilities."

Answered by AI

Has this procedure achieved official endorsement from the FDA?

"Our assessment of this treatment's safety is a 2, as it has yet to reach Phase 3 and demonstrate efficacy in clinical trials. However, existing data does indicate that the medication is safe for use."

Answered by AI

Is recruitment for this experiment ongoing?

"Affirmative. The clinicaltrials.gov database shows that this medical experiment, posted on March 1st 2021 and amended September 29th 2022, is actively seeking out volunteers. Fifty participants must be sourced from two different locations."

Answered by AI

Has this treatment method been examined in prior clinical experiments?

"At present, there are 2 active trials for this treatment but none of them have reached Phase 3 yet. Principal sites offering these clinical studies can be found in New Haven, Connecticut with additional locations participating as well."

Answered by AI
~10 spots leftby Jul 2024